Recent Pfizer Press Releases

  • 11/16/17 4:58 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). The approval was based on results from the S-TRAC trial that demonstrated a significant reduction in the risk of amore...
  • 11/13/17 9:20 am EST

    John Young named Group President, Pfizer Innovative Health
    Angela Hwang named Group President, Pfizer Essential Health

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that Albert Bourla has been named Chief Operating Officer effective January 1, 2018. “The naming of a Chief Operating Officer comes at a time when our business is strong as we continue to advance our strategy while also managing a dynamic and challenging external environment, said Ian Read, Pfizer Chairman and CEO. "The addition of a COO will enable me to spend more time focusing on themore...
  • 11/10/17 4:13 pm EST
    • Analyses from RWD program, ACROPOLIS, use two large U.S. databases to provide insights on Eliquis ® (apixaban), warfarin, and other direct oral anticoagulants in patients with NVAF at 2017 American Heart Association (AHA) Scientific Sessions
    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) plan to release real-world data (RWD) analyses of outcomes associated with direct oral anticoagulants (DOAC) among non-valvular atrial fibrillation (NVAF) patients using the U.S. Medicare database – the nation’s largest insurer handling more than one billion total claims per yeari – as well as the Department of Defense (DoD) Military Health System (MHS) during the 2017more...
  • 10/29/17 7:01 pm EDT

    Efficacy and safety profiles including immunogenicity were observed to be comparable between patients maintained on INFLECTRA or REMICADE and those switched to INFLECTRA from REMICADE ®**1

    NEW YORK--(BUSINESS WIRE)--New data show that switching patients with Crohn’s disease (CD) to INFLECTRA (infliximab CT-P13) from REMICADE (infliximab) led to comparable efficacy, safety and tolerability to treatment with REMICADE over a 24 week period.1 The full 54-week results of the randomized controlled trial comparing INFLECTRA and REMICADE in biologic-naïve patients with active CD support the long-term effectiveness of treatment with INFLECTRA.1 The results alsomore...
  • 10/16/17 7:00 am EDT

    Strong, durable responses seen against lung tumors and brain metastases across multiple lines of therapy

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced full results from the Phase 2 clinical trial of the investigational, next-generation tyrosine kinase inhibitor lorlatinib that exhibited clinically meaningful activity against lung tumors and brain metastases in a range of patients with ALK-positive and ROS1-positive advanced non-small cell lung cancer (NSCLC), including those who were heavily pretreated. Further, side effects were generally manageable andmore...
  • 10/12/17 8:00 am EDT

    New formulation may offer convenience to patients

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the United States Food and Drug Administration (FDA) has approved LYRICA® CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia (PHN). LYRICA CR did not receive approval for the management of fibromyalgia. “LYRICA CR was developed to offermore...
  • 10/10/17 6:45 am EDT

    One of the Largest Over-the-Counter (OTC) Health Care Products Businesses

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it is reviewing strategic alternatives for its Consumer Healthcare business. A range of options will be considered, including a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction, and Pfizer may ultimately determine to retain the business. Today’s announcement is part of Pfizer’s continuing efforts to allocate resources and capital to bestmore...
  • 10/5/17 8:00 am EDT

    Pfizer Oncology Together provides dedicated social workers for people taking Pfizer Oncology medicines

    This is Living with Cancer™ provides innovative resources for all cancer patients

    NEW YORK--(BUSINESS WIRE)--Pfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer Oncology medicines that offers dedicated social workers called ‘Care Champions’ to help navigate the complexities that accompany treatment, such as identifying resources to help find emotional support, and workplace transition, transportation and financial assistance. Formore...
  • 9/27/17 8:30 am EDT
    NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 32-cent fourth-quarter 2017 dividend on the company’s common stock, payable December 1, 2017, to shareholders of record at the close of business on November 10, 2017. The fourth-quarter 2017 cash dividend will be the 316th consecutive quarterly dividend paid by Pfizer. Working together for a healthier world® At Pfizer, we apply science and our global resources to bringmore...
  • 9/26/17 9:21 am EDT

    LaBelle Seeks to Inspire Boomers 65 and Older to Get “A New Attitude” About Adult Vaccinations as Part of Pfizer’s All About Your Boom™ Campaign

    NEW YORK--(BUSINESS WIRE)--Like many Baby Boomers, award-winning entertainer and music icon Patti LaBelle takes steps to stay healthy, including exercising and eating right. Yet, despite being a health-conscious Boomer, LaBelle knows there are diseases that can take her out of her routine: such as pneumococcal pneumonia, a potentially serious bacterial lung disease.1 That’s why LaBelle has joined Pfizer Inc to help launch All About Your Boom™, a public awareness campaignmore...